Get the Stockscreener App
35.27
3.58%
1.22
After Hours:
35.25
-0.02
-0.06%
Royalty Pharma Plc stock is traded at $35.27, with a volume of 8.95M.
It is up +3.58% in the last 24 hours and up +5.76% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$34.05
Open:
$34.14
24h Volume:
8.95M
Relative Volume:
2.00
Market Cap:
$14.22B
Revenue:
$2.26B
Net Income/Loss:
$1.09B
P/E Ratio:
15.05
EPS:
2.3431
Net Cash Flow:
$2.70B
1W Performance:
+4.50%
1M Performance:
+5.76%
6M Performance:
+39.90%
1Y Performance:
+29.67%
1-Day Range:
$34.14
$35.37
1-Week Range:
$33.37
$35.37
52-Week Range:
$24.05
$35.37
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
35.27 | 14.22B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.06 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.84 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
304.67 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
586.76 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
276.53 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Pallas Capital Advisors LLC Purchases 8,113 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week HighHere's Why - MarketBeat
Royalty Pharma stock hits 52-week high at $34.33 amid robust growth - Investing.com
Handelsbanken Fonder AB Decreases Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Wedge Capital Management L L P NC Buys Shares of 1,014,799 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com Nigeria
RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives - Yahoo Finance
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Ameriprise Financial Inc. - MarketBeat
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Royalty Pharma to Share Strategic Updates at Goldman Sachs Healthcare Conference 2025 - Stock Titan
(RPRX) Technical Data - news.stocktradersdaily.com
Mackenzie Financial Corp Increases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
33,531 Shares in Royalty Pharma plc (NASDAQ:RPRX) Acquired by 111 Capital - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) On An Uptrend: Could Fundamentals Be Driving The Stock? - Yahoo Finance
150,344 Shares in Royalty Pharma plc (NASDAQ:RPRX) Acquired by Lansforsakringar Fondforvaltning AB publ - MarketBeat
California State Teachers Retirement System Purchases 104,338 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Position Trimmed by Tidal Investments LLC - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 350,315 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
GF Fund Management CO. LTD. Invests $238,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Squarepoint Ops LLC Lowers Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
Janus Henderson Group PLC Decreases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
University of Texas Texas AM Investment Management Co. Purchases New Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Nuveen Asset Management LLC Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Quantinno Capital Management LP Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
State of Wyoming Has $385,000 Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Captrust Financial Advisors Lowers Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Two Sigma Investments LP Has $61.74 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Worldquant Millennium Advisors LLC Has $15.57 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Point72 Asset Management L.P. - MarketBeat
USS Investment Management Ltd Lowers Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
How to Take Advantage of moves in (RPRX) - news.stocktradersdaily.com
Raiffeisen Bank International AG Makes New $506,000 Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Two Sigma Advisers LP Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma - insights.citeline.com
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Man Group plc - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Stock Rating Lowered by StockNews.com - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Ethic Inc. - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.96%
1.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):